Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev). These therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space by examining the current medical practice, including the clinical and commercial outlook for pirfenidone and nintedanib; identifying the areas of pressing unmet need in the treatment of IPF; and assessing emerging therapies, including United Therapeutics’ inhaled treprostinil and Boehringer Ingelheim's PO-administered BI-1015550.
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.